The effectiveness of biological and targeted therapy in seropositive and seronegative rheumatoid arthritis


Authors: K. Pavelka 1;  M. Svoboda 2;  Z. Křístková 2
Authors‘ workplace: Revmatologický ústav Praha 1;  Institut biostatistiky a analýz, s. r. o., Brno 2
Published in: Čes. Revmatol., 28, 2020, No. 2, p. 72-78.
Category: Original article

Overview

This review focuses on the issue of the effectiveness of 
biological and targeted treatment in seropositive and 
seronegative patients with rheumatoid arthritis. Rando-mized trials preferentially enroll strongly active patients, i.e. mostly seropositive, with a minority of patients being seronegative. Therefore, the evidence of efficacy in seronegative patients comes primarily from meta-analyses of open-label extensions and registries. Due to different methodologies, results are sometimes inconsistent. However, a larger body of evidence demonstrates that rituximab and abatacept are more effective in seropositive patients, and a trend for efficacy has also been shown for tocilizumab. In contrast, anti-TNF drugs are as effective in both seropositive and seronegative patients. In randomized controlled trials, tofacitinib was more effective in seropositive than in seronegative patients.

In conclusion, although some differences in the efficacy of biological and targeted drugs have been found between seropositive and seronegative patients, the differences are not so large as to be the only selection criterion in the selection of a biological or targeted drug.

Keywords:

rheumatoid arthritis – RF and anti-CCP positivity – biological and targeted therapy


Sources

1. England BR, Thiele GM, Mikuls TR. Anticitrullinated protein antibodies: origin and role in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 2017; 29(1): 57–64.

2. Pratt AG, Isaacs JD. Séronegative rheumatoid arthritis: pathogenetic and therapeutic aspects. Best Pract Res Clin Rheumatol 2014; 28(4): 651–659.

3. Smolen J, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease – modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960–977.

4. Verstappen S, Lunt M, Bunn K. In patients with early inflammatory polyarthritis. ACPA positivity, younger age and inef-ficacy of the first non – biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis register. Ann Rheum Dis 2011; 70: 1428–1432.

5. Lv Q, Xin Y, Xin L, et al. The status of rheumatoid factor and anti CCP are not associated with effect of anti TNF alpha agent treatment in patients with rheumatoid arthritis. A metaanalysis. PLoS One 2014; 9(2): e89442. doi:10.1371/jopurnal.pone.0089442

6. Šenolt L, Mann H, Závada J, Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. Čes. Revmatol. 2017; 1: 8–24.

7. Szodaray P, Alex P, Dandapani V, et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 2004; 60: 209–218.

8. Chatzidionysiu K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in antibody positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575–1580.

9. de Kayser, Hoffman I, Durez P, et al. MIRA study group. Long term follow up of rituximab therapy in patients with rheumatoid arthritis. Results from the Belgian Mab Thera in Rheumatoid Arthritis Registry. J Rheumatol 2014; 41: 1761–1765.

10. Gottenberg JH, Ravaud P, Cantagrel A. Positivity for anti-cyclic citriulinated peptide is associated with a better response to abatacept. Data from the Orencia and Rheumatoid Arthritis registry. Ann Rheum Dis 2012; 71: 1815–1819.

11. Nusslein HG, Alten R, Galeazzi M, et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent, an interim analysis from observational prospective. ACTION study. BMC Musculosceletal Disird 2015; 16: 176.

12. Gottenberg JE, Courvoisier DS, Hernandez V, et al. Association of rheumatoid factor and anti CCP positivity with better effectiveness of abatacept. Results from Pan. European Registry Analysis. Arthritis Rheumatology 2016; 68: 1346–1352.

13. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014; 73: 86–94.

14. Pieper J, Herrath J, Rughavan S, et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in antibody-positive rheumatoid arthritis patients. BMC Immunol 2013; 14: 34.

15. Gabay C, Riek M, Hetland ML, et al. Effectiveness of tocilizumab with and without synthetic disease modifying antirheumatic drugs: results from a European collaborative study. Ann rheum Dis 2016; 75: 1336–1342.

16. Cappeli LC, Palmer IL, Kremer J, et al. Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. Semin Arthritis Rheum 2017; 47: 165–169.

17. Martin-Mola E, Gardia-Vicuna R, Gomez-Reino J, et al. Anti citrulinated peptide antibodies and their value for predicting responses to biologic agents. A review. Rheumatol Int 2016; 36: 1043–1063.

18. Courvoisier DS, Chatzi DK, Mongin D. The impact of seropositivity on the effectiveness of biologic antirheumatic drugs. Předloženo k publikaci.

19. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with MTX and adalimumab with MTX in patients with RA (ORAL Strategy), a phase 3b/4 double blind, head to head, randomised controlled trial. Lancet 2017; 390: 457–468.

20. Taylor P, Keystone EC, van der Heide D, et al. Baricitinib versus placebo or adalimumab in Rheumatoid arthritis. N Engl J Med 2017; 376: 652–662.

21. Bird P, Hall S, Nash P, et al. Treatment outcomes in patients with séropositive versus séronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD Open 2019; 5(1): e000742. doi:10.1136/rmdopen-2018-000742

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

×